BioCentury | Feb 20, 2020

With $88M series B, Spruce seeks short path to approval in rare endocrine disorder

Spruce Biosciences hopes two rounds of financing will be enough to deliver pivotal data for its lead program, which takes a non-steroidal approach to treating endocrine disorders such as classic congenital adrenal hyperplasia (CAH). Omega...
BC Week In Review | Jun 15, 2015
Clinical News

NBI-77860 regulatory update

Neurocrine said FDA placed a partial clinical hold on NBI-77860 and that the biotech suspended 2 planned clinical studies of the compound to treat congenital adrenal hyperplasia (CAH) based on preclinical data. The trials include...
BC Innovations | Sep 18, 2014
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology Aquaporin-4 (AQP4); corticotropin-releasing factor 1 (CRF1); corticotropin-releasing factor receptor 1 (CRHR1; CRFR1) Rat studies suggest inhibiting CRFR1 signaling could help prevent hypoxia-induced cerebral edema,...
BC Innovations | Aug 22, 2013
Cover Story

Deep pockets

The B class of GPCRs is brimming with therapeutic targets, but thus far, development of small molecule drugs has been stymied. New studies reporting the first-ever crystal structures of members of the family could change...
BC Innovations | Jun 28, 2012

Pharma compounds at the crossroads

The National Center for Advancing Translational Sciences (NCATS) has disclosed details about the first library of therapeutics in its Discovering New Therapeutic Uses for Existing Molecules program ( see "Repurposing pharma compounds"). The compounds provided by...
BC Innovations | Oct 13, 2011
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Corticotropin-releasing factor 1 (CRF1); microtubule-associated protein-t (MAPT; TAU; FTDP-17) Mouse studies suggest antagonists of the stress response hormone CRF1 could help prevent...
BC Week In Review | May 2, 2011
Clinical News

SSR125543: Phase II discontinued

sanofi-aventis disclosed in its 1Q11 earnings that it discontinued the double-blind, international Phase II AGATE trial of SSR125543 in patients with MDD after the compound missed the primary endpoint of significantly improving HAM-D scores from...
BC Extra | Apr 29, 2011
Company News

sanofi ends Metabolex deal

sanofi-aventis Group (Euronext:SAN; NYSE:SNY) terminated a 2010 deal with Metabolex Inc. (Hayward, Calif.) and returned rights to diabetes candidate SAR260093/ MBX-2982 . Metabolex said sanofi made its decision after reviewing data from a completed Phase II...
BC Innovations | Mar 17, 2011
Targets & Mechanisms

The hormone trigger in PTSD

Post-traumatic stress disorder is thought to involve changes in the circuitry of brain regions related to fear, although the specific molecular players have been elusive. Now, U.S. researchers have evidence that dysregulation of a brain...
BC Innovations | Sep 17, 2009
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Anxiety; depression Corticotropin-releasing factor (CRF1); CRF1 receptor 1 (CRHR1; CRFR1) A study in animals identified a pyrazinone-based CRHR1 antagonist that could help treat anxiety,...
Items per page:
1 - 10 of 38